Transparency Council

28 January, 2025

24 January, 2025

24 January, 2025

24 January, 2025

24 January, 2025

24 January, 2025

24 January, 2025

23 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

17 January, 2025

14 January, 2025

14 January, 2025

10 January, 2025

10 January, 2025

10 January, 2025

10 January, 2025

10 January, 2025

10 January, 2025

Pokaż więcej ↓

Pokaż mniej ↑

Transparency Council

The Transparency Council meeting 5/2025 on 3 February 2025

Communication of the meeting of Transparency Council No. 3/2025 on 20 January 2025

Position of the Transparency Council – Rythmodan (disopyramide)

Position of the Transparency Council – Nucala (mepolizumab)

Position of the Transparency Council – HyQvia (human normal immunoglobulin)

Position of the Transparency Council – Verzenios (abemaciclib)

Position of the Transparency Council – Forxiga (dapagliflozin)

The Transparency Council meeting 4/2025 on 27 January 2025

Opinion of the Transparency Council – sirolimusum

Opinion of the Transparency Council – tacrolimusum

Opinion of the Transparency Council – everolimusum

Opinion of the Transparency Council – azathioprinum

Opinion of the Transparency Council – acidum mycophenolicum

Opinion of the Transparency Council – vigabatrinum

Position of the Transparency Council – Ocrevus (ocrelizumab)

Communication of the meeting of Transparency Council No. 2/2025 on 13 January 2025

Position of the Transparency Council – Alecensa (alectinib)

Communication of the meeting of Transparency Council No. 1/2025 on 7 January 2025

The Transparency Council meeting 2/2025 on 13 January 2025

The Transparency Council meeting 3/2025 on 20 January 2025

Position of the Transparency Council – Forxiga (dapagliflozin)

Position of the Transparency Council – cholestyramine

Position of the Transparency Council – Attentin (dextroamphetamine)

Position of the Transparency Council – cytology screening (classic cytology)